中国新冠病毒灭活疫苗研发综述：聚焦特殊人群的安全性与有效性

A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.

作者信息

Hu Lidan, Sun Jingmiao, Wang Yan, Tan Danny, Cao Zhongkai, Gao Langping, Guan Yuelin, Jia Xiuwei, Mao Jianhua

机构信息

Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310030, China.

出版信息

Vaccines (Basel). 2023 May 31;11(6):1045. doi: 10.3390/vaccines11061045.

DOI:10.3390/vaccines11061045

PMID:37376434

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10302808/

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been widespread globally, and vaccination is critical for preventing further spread or resurgence of the outbreak. Inactivated vaccines made from whole inactivated SARS-CoV-2 virus particles generated in Vero cells are currently the most widely used COVID-19 vaccines, with China being the largest producer of inactivated vaccines. As a result, the focus of this review is on inactivated vaccines, with a multidimensional analysis of the development process, platforms, safety, and efficacy in special populations. Overall, inactivated vaccines are a safe option, and we hope that the review will serve as a foundation for further development of COVID-19 vaccines, thus strengthening the defense against the pandemic caused by SARS-CoV-2.

摘要

2019冠状病毒病（COVID-19）大流行由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，已在全球广泛传播，接种疫苗对于预防疫情的进一步传播或复发至关重要。由在Vero细胞中产生的全灭活SARS-CoV-2病毒颗粒制成的灭活疫苗是目前使用最广泛的COVID-19疫苗，中国是灭活疫苗的最大生产国。因此，本综述的重点是灭活疫苗，对其研发过程、平台、安全性以及在特殊人群中的疗效进行多维度分析。总体而言，灭活疫苗是一种安全的选择，我们希望本综述能为COVID-19疫苗的进一步研发奠定基础，从而加强对SARS-CoV-2所致大流行的防御。